AbbVie
ABBV
#25
Rank
NZ$897.95 B
Marketcap
NZ$508.15
Share price
-0.14%
Change (1 day)
29.16%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2026 (TTM): NZ$15.18 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$64.38 Billion. In 2025 the company made an earning of NZ$11.72 Billion, an increase over its 2024 earnings that were of NZ$6.60 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$15.18 B29.52%
2025 NZ$11.72 B77.53%
2024 NZ$6.60 B-40.54%
2023 NZ$11.10 B-53.62%
2022 NZ$23.94 B3.76%
2021 NZ$23.07 B282.25%
2020 NZ$6.03 B-59.67%
2019 NZ$14.97 B62.13%
2018 NZ$9.23 B-32.74%
2017 NZ$13.72 B-1.99%
2016 NZ$14.00 B18.65%
2015 NZ$11.80 B180.5%
2014 NZ$4.20 B-55.57%
2013 NZ$9.47 B-6.86%
2012 NZ$10.17 B56.05%
2011 NZ$6.51 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$12.27 B-20.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$59.69 B 286.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$18.27 B 18.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$1.79 B-88.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
-NZ$3.48 Billion-122.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$21.16 B 36.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$25.46 B 64.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$14.01 B-9.31%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$1.45 B-90.59%๐Ÿ‡บ๐Ÿ‡ธ USA